Detail akcie Anthera Pharmact Rg online

Business Summary: Anthera Pharmaceuticals, Inc. (Anthera) is a biopharmaceutical company focused on developing and commercializing products to treat serious diseases associated with inflammation, including enzyme replacement therapies and autoimmune diseases. The Company has two Phase III product candidates, liprotamase also known as Sollpura and blisibimod. Sollpura is a non-porcine investigational Pancreatic Enzyme Replacement Therapy (PERT) intended for the treatment of patients with Exocrine Pancreatic Insufficiency (EPI), often seen in patients with cystic fibrosis and other conditions. Blisibimod targets B-cell activating factor (BAFF), which has been shown to be elevated in a range of B-cell mediated autoimmune diseases, including systemic lupus erythematosus (SLE), or lupus, Immunoglobulin A nephropathy (IgA) nephropathy, lupus nephritis and others.
Financial Summary: BRIEF: For the three months ended 31 March 2018, Anthera Pharmaceuticals Inc revenues was not reported. Net loss applicable to common stockholders decreased 32% to $9.3M. Lower net loss reflects Fair value of warrant liability in exces decrease from $600K (expense) to $0K. Basic Earnings per Share excluding Extraordinary Items increased from -$2.03 to -$0.42.